(Q36229821)

English

Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases

scientific article published on February 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

10.1084/JEM.173.2.313

https://api.crossref.org/works/10.1084/JEM.173.2.313

25 October 2022

2

object named as

L. Gabriele

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

7

object named as

U. Testa

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

author name string

V. Ciolli

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

P. Sestili

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

F. Varano

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

E. Proietti

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

I. Gresser

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

E. Montesoro

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

D. Bulgarini

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

G. Mariani

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

language of work or name

0 references

publication date

1 February 1991

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

full work available at URL

https://europepmc.org/articles/PMC2118774

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

https://europepmc.org/articles/PMC2118774?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1671080

25 October 2022

http://rupress.org/jem/article-pdf/173/2/313/1101321/313.pdf

Portable Document Format

1 reference

10.1084/JEM.173.2.313

https://api.crossref.org/works/10.1084/JEM.173.2.313

25 October 2022

Journal of Experimental Medicine

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

173

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

313-322

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2118774

1 October 2017

Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2118774

1 October 2017

The biology of interleukin 1 and comparison to tumor necrosis factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2118774

1 October 2017

Human interleukin 2: molecular biology, physiology and clinical possibilities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2118774

1 October 2017

Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2118774

29 June 2018

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2118774

22 September 2018

Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2118774

22 September 2018

Effectiveness of mouse interferon alpha/beta compared to single-agent chemotherapy in increasing survival time of mice after intravenous inoculation of Friend erythroleukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-1 beta induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti-tumor effects of tumor necrosis factor alpha or beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor alpha induces early morphologic and metabolic alterations in Friend leukemia cell tumors and fibrosarcomas in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. V. Comparisons with the action of tumor necrosis factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isolation of interferon-resistant variants of friend erythroleukemia cells: Effects of interferon and ouabain

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. II. Changes in cell surface glycoproteins associated with a highly malignant phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1671080

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1084/JEM.173.2.313

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36229821&oldid=1760695579"